2025-09-23 - Analysis Report
Okay, here's a report analyzing Recursion Pharmaceuticals (RXRX) based on the data you provided.

## Recursion Pharmaceuticals (RXRX) Analysis

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **Ticker:** RXRX
*   **Cumulative Return:** -45.96%
*   **VOO Cumulative Return:** 46.07%
*   **Divergence:**
    *   Max: 35.8
    *   Min: -92.3
    *   Current: -90.8
    *   Relative Divergence: 1.2

**Analysis:** RXRX has significantly underperformed the S&P 500 (VOO) over the period. The current divergence is near its historical low, indicating substantial underperformance. The relative divergence of 1.2 suggests that the current divergence is near the bottom end of its historical range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha    | Beta  | Cap(B) |
|------------|--------|-------|----------|-------|--------|
| 2021-2023  | 5.0%   | 73.6% | -1.0%    | -0.1  | 4.3    |
| 2022-2024  | 0.0%   | 73.6% | -25.0%   | 0.1   | 3.0    |
| 2023-2025  | 6.0%   | 73.6% | -53.0%   | 0.1   | 2.1    |

**Analysis:** The Alpha and Beta analysis reveals several key insights:

*   **CAGR:** The Compound Annual Growth Rate (CAGR) is modest, varying between 0.0% and 6.0% across different periods.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high at 73.6%, indicating significant downside risk.
*   **Alpha:** The Alpha values are negative and decreasing, suggesting RXRX has consistently underperformed relative to its benchmark. In the 2023-2025 period, the Alpha is -53.0%, indicating substantial underperformance.
*   **Beta:** The Beta values are around 0.1, suggesting that RXRX has low volatility relative to the market.
*   **Cap(B):** The market capitalization has decreased from $4.3B in 2021-2023 to $2.1B in 2023-2025, indicating a significant decline in company value.

### 2. Recent Price Action

*   **Current Price:** 4.91
*   **Last-market:** price=4.98, previousClose=4.91, change=1.43%
*   **5-day Moving Average:** 4.83
*   **20-day Moving Average:** 4.76
*   **60-day Moving Average:** 5.30

**Analysis:** The current price is above both the 5-day and 20-day moving averages, suggesting short-term upward momentum. However, it's still below the 60-day moving average, indicating potential resistance. The recent price change of 1.43% suggests a recent upward movement, further supported by the price increase in the last market.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3367 (Low Risk)
*   **RSI:** 57.55
*   **PPO:** 1.10
*   **Hybrid Signal:** Cash 0%, Buy 80% of cash (Caution - MRI: 0.33)
*   **20-day Relative Divergence Change:** 1.2 (Positive - Short-term Increase)
*   **Expected Return:** -2235.1%

**Analysis:**

*   The MRI indicates **Low Risk**, suggesting a stable market environment for RXRX.
*   The RSI of 57.55 is approaching overbought territory (70+), indicating increasing buying pressure.
*   The PPO of 1.10 is positive, suggesting that the short-term moving average is above the long-term moving average, signaling potential bullish momentum.
*   The Hybrid Signal recommends buying 80% of cash with caution, given the MRI.
*   The recent positive change in relative divergence (1.2) supports a short-term upward trend.
*   **Expected Return:** The very negative expected return (-2235.1%) suggests significant concerns about long-term profitability and/or potential risks associated with the company.

### 4. Recent News & Significant Events

*   **[2025-09-22]** Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why (Zacks)
*   **[2025-09-21]** Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances (Insider Monkey)
*   **[2025-09-15]** Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know (Zacks)
*   **[2025-09-15]** Needham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8 (Insider Monkey)
*   **[2025-09-12]** Recursion Pharmaceuticals Insider Sold Shares Worth $471,000, According to a Recent SEC Filing (MT Newswires)
*   **[2025-09-03]** Rallybio Receives $12.5 Million Equity Milestone From Recursion (MT Newswires)

**Analysis:**

*   The news is mixed. While there's positive news regarding a milestone payment from Rallybio and Needham's "Buy" rating, there's also negative news about the stock sinking as the market gains and an insider selling shares.
*   The headline "Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why" suggests an analysis of the company's recent performance, but the context of the performance (positive or negative) is not immediately clear from the title. It's something to investigate further by reading the article.

### 4-2. Analyst Opinions

*   **Consensus:** Hold (Mean: 2.62)
*   **Opinions:** 6
*   **Target Price:**
    *   Average: 6.47
    *   High: 10.00
    *   Low: 3.00

**Analysis:** Analyst consensus is "Hold," suggesting a neutral outlook on the stock. The average target price of $6.47 indicates a potential upside from the current price (4.91), but the wide range between the high and low target prices suggests uncertainty among analysts.

### 5. Recent Earnings Analysis

| 날짜         | EPS   | 매출       |
|--------------|-------|------------|
| 2025-08-05   | -0.41 | 0.02 B$    |
| 2025-05-05   | -0.5  | 0.01 B$    |
| 2024-11-06   | -0.34 | 0.03 B$    |
| 2024-08-08   | -0.4  | 0.01 B$    |
| 2025-08-05   | -0.4  | 0.01 B$    |

**Analysis:** The company is consistently reporting negative EPS, which is concerning. Revenue fluctuates, but remains relatively low. This suggests the company is struggling to achieve profitability.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $0.02B     | -5.54%        |
| 2025-03-31   | $0.01B     | -47.31%       |
| 2024-12-31   | $0.00B     | -183.62%      |
| 2024-09-30   | $0.03B     | 53.69%        |
| 2024-06-30   | $0.01B     | 36.14%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE        |
|--------------|------------|------------|
| 2025-06-30   | $0.92B     | -18.70%    |
| 2025-03-31   | $0.93B     | -21.68%    |
| 2024-12-31   | $1.03B     | -17.29%    |
| 2024-09-30   | $0.52B     | -18.27%    |
| 2024-06-30   | $0.58B     | -16.69%    |

**Analysis:**

*   **Revenue and Profitability:** Revenue is low and inconsistent. Profit margins are mostly negative, indicating the company is struggling to generate profits from its revenue. The high negative profit margin in 2024-12-31 is particularly concerning.
*   **Capital and Profitability:** While the company has significant equity, the negative ROE values indicate that it is not effectively utilizing its equity to generate profits.

### 7. Overall Assessment

RXRX is a high-risk, high-reward investment. Here's a summary of the key takeaways:

*   **Underperformance:** RXRX has significantly underperformed the S&P 500.
*   **Financials:** Negative EPS, inconsistent revenue, and negative profit margins raise concerns about the company's financial health.  The negative ROE further emphasizes the company's difficulty in generating profit from its equity.
*   **Technicals:** Short-term technical indicators suggest some upward momentum, but the long-term outlook is uncertain.
*   **News:** Mixed news flow, with positive developments offset by negative events and insider selling.
*   **Analyst Opinion:** Neutral analyst consensus with a wide range of target prices.
*   **MRI:** Low Risk market environment but be caution of large negative expected return

**In conclusion, while there are some positive signals, the negative financial performance, underperformance relative to the market, and mixed news flow warrant caution. The incredibly negative expected return should be a significant red flag for potential investors.**
